Antibe Therapeutics

Antibe Reports Q2 2024 Interim Financial and Operating Results

Retrieved on: 
Monday, November 13, 2023

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to develop next-generation therapies to target inflammation, has filed its financial and operating results for the fiscal quarter ended September 30, 2023.

Key Points: 
  • Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to develop next-generation therapies to target inflammation, has filed its financial and operating results for the fiscal quarter ended September 30, 2023.
  • While trial initiation remains set for calendar Q1 2024, the Company now anticipates top-line results in calendar Q3 2024.
  • General and Administrative Expenses: General and administrative expenses were $1.9 million, compared to $1.7 million in fiscal Q2 2023.
  • The Company’s unaudited fiscal Q2 2024 condensed interim financial statements and MD&A are available on SEDAR.

Antibe Reports 2023 Year-End Results and Business Highlights

Retrieved on: 
Thursday, June 29, 2023

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation therapies to target inflammation, has filed its financial and operating results for the fiscal year ended March 31, 2023.

Key Points: 
  • Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation therapies to target inflammation, has filed its financial and operating results for the fiscal year ended March 31, 2023.
  • “We made excellent progress in the year, much of it behind the scenes,” commented Dan Legault, Antibe’s CEO.
  • “Foremost is the successful transition to otenaproxesul’s faster-absorbing formulation, a significant step that involved launching a new production process in a new plant.
  • The Company’s audited fiscal 2023 consolidated financial statements, MD&A and AIF are available on SEDAR.

Antibe Provides April 2023 Corporate Update

Retrieved on: 
Tuesday, April 11, 2023

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, is pleased to provide a corporate update.

Key Points: 
  • Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, is pleased to provide a corporate update.
  • Further to Antibe’s update of February 15, 2023, the Company has now selected a clinical research organization (“CRO”) to carry out the pharmacokinetic/pharmacodynamic (“PK/PD”) study for otenaproxesul’s new formulation.
  • Antibe has concluded a comprehensive strategic positioning assessment of otenaproxesul for acute pain in the U.S. market.
  • As noted in its February update, the Company has selected lead and back-up candidates for its inflammatory bowel disease (“IBD”) program.

Antibe Reports Q3 2023 Interim Financial and Operating Results

Retrieved on: 
Wednesday, February 15, 2023

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, has filed its financial and operating results for the fiscal quarter ended December 31, 2022.

Key Points: 
  • Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, has filed its financial and operating results for the fiscal quarter ended December 31, 2022.
  • To de-risk the translation of this data to human doses, we've planned a confirmatory study in healthy volunteers upon release of the new drug tablets.
  • General and Administrative Expenses: General and administrative expenses were $1.6 million for the quarter, compared to $1.3 million in fiscal Q3 2022.
  • The Company’s unaudited fiscal Q3 2023 condensed interim financial statements and MD&A are available on SEDAR.

Antibe Reports Q2 2023 Interim Financial and Operating Results

Retrieved on: 
Tuesday, November 15, 2022

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, has filed its financial and operating results for the fiscal quarter ended September 30, 2022.

Key Points: 
  • Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, has filed its financial and operating results for the fiscal quarter ended September 30, 2022.
  • And we remain on track to initiate the Phase II bunionectomy study in the first half of next year.
  • General and Administrative Expenses: General and administrative expenses were $1.7 million for the quarter, compared to $1.7 million in fiscal Q2 2022.
  • The Companys unaudited fiscal Q2 2023 condensed interim financial statements and MD&A are available on SEDAR.

Antibe Closes Previously Announced Strategic Sale of Citagenix Subsidiary

Retrieved on: 
Wednesday, November 2, 2022

Importantly, it provides non-dilutive funding for our pipeline and fortifies our already strong balance sheet.

Key Points: 
  • Importantly, it provides non-dilutive funding for our pipeline and fortifies our already strong balance sheet.
  • And of course, we wish the Citagenix and HANSAmed team the very best.
  • Antibe is a clinical-stage biotechnology company leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions.
  • The Companys anticipated next target is inflammatory bowel disease (IBD), a condition long in need of safer, more effective therapies.

Antibe Provides Development Update for Otenaproxesul

Retrieved on: 
Wednesday, October 12, 2022

The lower dose provides an additional safety buffer as well as a potential pathway to address chronic pain indications.

Key Points: 
  • The lower dose provides an additional safety buffer as well as a potential pathway to address chronic pain indications.
  • The new formulation was developed in collaboration with Antibes global manufacturing partner; all related IP is owned exclusively by Antibe.
  • Antibes lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids and todays NSAIDs for acute pain.
  • The Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.

Antibe Announces Results of 2022 Annual Meeting

Retrieved on: 
Friday, September 9, 2022

Voting results on all matters voted on at the Meeting have been filed on SEDAR.

Key Points: 
  • Voting results on all matters voted on at the Meeting have been filed on SEDAR.
  • Antibe is a clinical stage biotechnology company leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions.
  • The Companys current pipeline includes assets that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs).
  • Antibes lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids and todays NSAIDs for acute pain.

Antibe Academic Collaborator to Present Clinical Data at PAINWeek 2022

Retrieved on: 
Tuesday, September 6, 2022

The poster will be presented by the lead author of the study and Antibe academic collaborator, James R.W.

Key Points: 
  • The poster will be presented by the lead author of the study and Antibe academic collaborator, James R.W.
  • Im delighted to have the opportunity to share our clinical data at PAINWeek, commented Dr. Glanville.
  • Held annually, the PAINWeek National Conference is the largest U.S. conference for frontline healthcare professionals with an interest in pain management.
  • Antibes lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids and todays NSAIDs for acute pain.

Antibe Therapeutics Reports Q1 2023 Interim Financial and Operating Results

Retrieved on: 
Monday, August 15, 2022

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, has filed its financial and operating results for the fiscal quarter ended June 30, 2022.

Key Points: 
  • Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, has filed its financial and operating results for the fiscal quarter ended June 30, 2022.
  • The results of this study should allow us to identify the optimal dosing regimens for the larger Phase II bunionectomy trial next year.
  • General and Administrative Expenses: General and administrative expenses were $1.1 million for the quarter, compared to $1.3 million in fiscal Q1 2022.
  • The Companys unaudited fiscal Q1 2023 condensed interim financial statements and MD&A will be available shortly on SEDAR.